Switch theme
Sign up to access all valuation multiples
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
2008
680
LTM Revenue $1.2B
LTM EBITDA $199M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Progyny has a last 12-month revenue (LTM) of $1.2B and a last 12-month EBITDA of $199M.
In the most recent fiscal year, Progyny achieved revenue of $1.2B and an EBITDA of $70.6M.
Progyny expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Progyny valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| Gross Profit | $270M | XXX | $253M | XXX | XXX | XXX |
| Gross Margin | 23% | XXX | 22% | XXX | XXX | XXX |
| EBITDA | $199M | XXX | $70.6M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 6% | XXX | XXX | XXX |
| EBIT | $195M | XXX | $67.5M | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $52.2M | XXX | $54.3M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Progyny's stock price is $21.
Progyny has current market cap of $1.8B, and EV of $1.6B.
See Progyny trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $1.8B | XXX | XXX | XXX | XXX | $0.57 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Progyny has market cap of $1.8B and EV of $1.6B.
Progyny's trades at 1.4x EV/Revenue multiple, and 22.8x EV/EBITDA.
Equity research analysts estimate Progyny's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Progyny has a P/E ratio of 35.3x.
See valuation multiples for Progyny and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| EV (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 8.1x | XXX | 22.8x | XXX | XXX | XXX |
| EV/EBIT | 8.3x | XXX | 23.9x | XXX | XXX | XXX |
| EV/Gross Profit | 6.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 35.3x | XXX | 33.9x | XXX | XXX | XXX |
| EV/FCF | 10.3x | XXX | 9.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialProgyny's last 12 month revenue growth is 7%
Progyny's revenue per employee in the last FY averaged $1.7M, while opex per employee averaged $0.3M for the same period.
Progyny's rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Progyny's rule of X is 35% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Progyny and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 75% | XXX | XXX | XXX |
| Rule of 40 | 13% | XXX | 14% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 35% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Star Health Insurance | XXX | XXX | XXX | XXX | XXX | XXX |
| Hapvida | XXX | XXX | XXX | XXX | XXX | XXX |
| Qualicorp | XXX | XXX | XXX | XXX | XXX | XXX |
| Accolade | XXX | XXX | XXX | XXX | XXX | XXX |
| AIX Inc. | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Progyny acquired XXX companies to date.
Last acquisition by Progyny was XXXXXXXX, XXXXX XXXXX XXXXXX . Progyny acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Progyny founded? | Progyny was founded in 2008. |
| Where is Progyny headquartered? | Progyny is headquartered in United States of America. |
| How many employees does Progyny have? | As of today, Progyny has 680 employees. |
| Who is the CEO of Progyny? | Progyny's CEO is Mr. Peter Anevski. |
| Is Progyny publicy listed? | Yes, Progyny is a public company listed on NAS. |
| What is the stock symbol of Progyny? | Progyny trades under PGNY ticker. |
| When did Progyny go public? | Progyny went public in 2019. |
| Who are competitors of Progyny? | Similar companies to Progyny include e.g. Star Health Insurance, Hapvida, Qualicorp, Accolade. |
| What is the current market cap of Progyny? | Progyny's current market cap is $1.8B |
| What is the current revenue of Progyny? | Progyny's last 12 months revenue is $1.2B. |
| What is the current revenue growth of Progyny? | Progyny revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Progyny? | Current revenue multiple of Progyny is 1.4x. |
| Is Progyny profitable? | Yes, Progyny is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Progyny? | Progyny's last 12 months EBITDA is $199M. |
| What is Progyny's EBITDA margin? | Progyny's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Progyny? | Current EBITDA multiple of Progyny is 8.1x. |
| What is the current FCF of Progyny? | Progyny's last 12 months FCF is $157M. |
| What is Progyny's FCF margin? | Progyny's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Progyny? | Current FCF multiple of Progyny is 10.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
